Ovid Therapeutics (NASDAQ:OVID) reported positive topline results from its Phase 2 study evaluating soticlestat in children with Dravet syndrome or Lennox-Gastaut syndrome, two highly refractory epilepsy syndromes.
Patients receiving soticlestat had a 27.8% median reduction from baseline in convulsive and drop seizure frequency, compared with a 3.1% median increase in patients taking placebo, during the 12-week maintenance period.
During the full 20-week treatment period, patients receiving soticlestat had a 29.8% median reduction in convulsive and drop seizure frequency, compared with no change in median seizure frequency in patients taking placebo.
“We are extremely encouraged by these results, which show a clear statistically significant reduction of seizures in Dravet syndrome patients treated with soticlestat, as well as a trend for seizure reduction in Lennox-Gastaut patients,” Dr. Amit Rakhit, Ovid’s president and CMO, said in a statement.
Ovid plans to initiate a Phase 3 registrational program of soticlestat in Dravet syndrome in collaboration with Takeda Pharmaceuticals (NYSE:TAK).